Medine.co.uk

Taurador 5 Mg/Ml Pour-On Solution For Cattle

Issued December 2013

AN: 00282/2012

SUMMARY OF PRODUCT CHARACTERISTICS


1. NAME OF THE VETERINARY MEDICINAL PRODUCT


Taurador 5 mg/ml Pour-on Solution for Cattle [AT, BE, BG, CY, CZ, DK, EE, ES, FR, EL, HU, IE, IT, LV, LT, LU, MT, NL, PL, PT, RO, SL, SI, UK]


Taurador vet 5 mg/ml Pour-on Solution for Cattle [FI, SE]


Taurador vet 5 mg/ml Solution for Cattle [NO]


2. QUALITATIVE AND QUANTITATIVE COMPOSITION


Each ml contains:


Active substance:

Doramectin 5 mg


Excipient(s):

Brilliant blue FCF (E133) 0.007 mg

For a full list of excipients, see section 6.1.


3. PHARMACEUTICAL FORM


Pour-on Solution

A pale blue, clear solution


4. CLINICAL PARTICULARS


4.1 Target species


Cattle


4.2 Indications for use, specifying the target species


For treatment of gastrointestinal roundworms, lungworms, eyeworms, warbles, sucking and biting lice, mange mites and hornfly in cattle.


Gastrointestinal roundworms(adults and fourth stage larvae)

Ostertagia ostertagi (inc. inhibited larvae)

O. lyrata1

Haemonchus placei

Trichostrongylus axei

T. colubriformis

Cooperia oncophora

C. punctata1

C. surnabada1(syn. mcmasteri)

Bunostomum phlebotomum1

Oesophagostomum radiatum

Trichuris spp1

1adults


Lungworms(adults and fourth stage larvae)

Dictyocaulus viviparus

Eyeworms (adults)

Thelazia spp

Warbles(parasitic stages)

Hypoderma bovis, H. lineatum

Biting lice

Damalinia (Bovicola) bovis

Sucking lice

Haematopinus eurystemus,

Linognathus vituli,

Solenopotes capillatus

Mange mites

Psoroptes bovis,

Sarcoptes scabiei,

Chorioptes bovis

Horn fly

Haematobia irritans


Duration of activity


The veterinary product protects cattle against infection or re-infection with the following parasites for the periods indicated.


Species

Days

Ostertagia ostertagi

Cooperia oncophora

35

28

Dictyocaulus viviparus

42

Linognathis vituli

49

Oesophagostomum radiatum

21

Damalinia (Bovicola) bovis

42

Trichostrongylus axei

28

Solenopotes capillatus

35


The veterinary product also controls horn flies (Haematobia irritans) for at least 42 days after treatment.


4.3 Contraindications


The product has been formulated for topical application specifically for cattle. It should not be administered to other species as severe adverse reactions, including fatalities in dogs, may occur. See section 4.5 i.


Do not use in cases of known hypersensitivity to the active substance or any of the excipients.

4.4 Special warnings for each target species


For external use only.


Care should be taken to avoid the following practices because they increase the risk of development of resistance and could ultimately result in ineffective therapy:

- too frequent and repeated use of anthelmintics from the same class, over an extended period of time.

- under dosing, which may be due to underestimation of bodyweight, misadministration of the product, or lack of calibration of a dosing device (if any).


Suspected clinical cases of resistance to anthelmintics should be further investigated using appropriate tests (e.g. faecal egg count reduction test). Where the results of the test(s) strongly suggest resistance to a particular anthelmintic, an anthelmintic belonging to a different pharmacological class and having a different mode of action should be used.


Do not apply to areas of skin that are contaminated with mud or manure.


Therapeutic efficacy for internal and external parasites is not affected by heavy rainfall (2 cm in 1 hour) either before (20 minutes) or after (20 and 40 minutes) treatment. The influence of extreme weather conditions on efficacy is unknown.


4.5 Special precautions for use


i. Special precautions for use in animals.


Avermectins may not be well tolerated in all non-target species. Cases of intolerance with fatal outcome are reported in dogs, especially Collies, old English Sheepdogs and related breeds or crosses, and also in turtles/tortoise. Care should be taken to avoid ingestion of spilled product or access to containers by these other species.


To avoid secondary reactions due to death of Hypodermalarvae in the oesophagus or the spine, it is recommended to administer the veterinary product at the end of the period of warble fly activity and before the larvae reach their resting sites. Consult your veterinary surgeon on the correct timing of treatment.


ii. Special precautions to be taken by the person administering the veterinary medicinal product to animals.


Persons with known hypersensitivity to the active substance should avoid contact with the product. Do not smoke or eat while handling the product. Wash hands after use. The veterinary product may be irritating to human skin and eyes and users should be careful not to apply it to themselves or to other persons. Operators should wear rubber gloves and boots with a waterproof coat when applying the product. Protective clothing should be washed after use. If accidental skin contact occurs, wash the affected area immediately with soap and water. If accidental eye exposure occurs, flush the eyes immediately with water and get medical attention. Use only in well ventilated areas or outdoors.


Highly Flammable - Keep away from heat, sparks, open flame or other sources of ignition.


iii. Other precautions


Doramectin is very toxic to dung fauna. The risk to dung fauna can be reduced by avoiding too frequent and repeated use of doramectin (and products of the same anthelmintic class) in cattle.


4.6 Adverse reactions (frequency and seriousness)


In rare cases small skin lesions may occur at the administration site.


4.7 Use during pregnancy, lactation or lay


Do not use in non-lactating dairy cows, including pregnant heifers, within 60 days prior to calving.


4.8 Interaction with other medicinal products and other forms of interaction


None known.


4.9 Amounts to be administered and administration route


A single treatment of 500 ยตg of doramectin/kg bodyweight equivalent to 1 ml of product per 10 kg bodyweight, applied topically along the mid-line of the back in a narrow strip between the withers and tailhead.


To ensure administration of a correct dose, bodyweight should be determined as accurately as possible; accuracy of the dosing device should be checked.


If animals are to be treated collectively rather than individually, they should be grouped according to their bodyweight and dosed accordingly, in order to avoid under- and over- dosing.


4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary


Overdoses up to 5 times the label recommended dose resulted in no clinical signs that could be attributed to treatment with doramectin.



4.11 Withdrawal period(s)


Meat and offal: 35 days.


Do not use in lactating cows used to produce milk for human consumption, or in dry cows or pregnant dairy heifers within 60 days prior to calving.


5. PHARMACOLOGICAL PROPERTIES


Pharmacotherapeutic group: Antiparasitic Products Insecticides and Repellents/Endectocides

ATCvet Code: QP 54AA03


5.1 Pharmacodynamic properties

Doramectin is a fermentation-derived antiparasitic agent, which belongs to the avermectin class, and is closely related structurally to ivermectin. Both compounds share a wide spectrum of antiparasitic activity and produce a similar paralysis in nematodes and parasitic arthropods. Whilst it is not possible to assign a single mode of action to the avermectins, it is likely that the entire series share a common mechanism. In parasitic organisms the effect is mediated through a specific avermectin-binding site. The physiological response to avermectin binding is an increase in membrane permeability to chloride ions. In invertebrate nervous tissue an influx of chloride ions into the excitatory motor neurone in nematodes or muscle cell of arthropods results in hyperpolarisation and the elimination of signal transmission with resulting paralysis.


5.2 Pharmacokinetic particulars


Maximum plasma concentration of doramectin occurs in cattle approximately 9 days after topical administration of the veterinary product. An (apparent) elimination half-life of around 10 days results in sustained doramectin concentrations, which protect animals from parasitic infection and re-infection for extended periods following treatment.


5.3 Environmental properties

Doramectin is very toxic to aquatic organisms. Like other macrocyclic lactones, doramectin has the potential to adversely affect non-target organisms. Following treatment, excretion of potentially toxic levels of doramectin may take place over a period of several weeks. Faeces containing doramectin excreted onto pasture by treated animals may reduce the abundance of dung feeding organisms which may impact on the dung degradation.


6. PHARMACEUTICAL PARTICULARS


6.1 List of excipients


Brilliant blue FCF (E133)

Cetearyl Octanoate

Isopropyl alcohol

Purified Water

Trolamine


6.2 Incompatibilities


None known.

6.3 Shelf life


Shelf life of the veterinary medicinal product as packaged for sale: 3 years.

Shelf life after first opening the immediate packaging: 3 months.


6.4. Special precautions for storage


Protect from light.

Do not refrigerate.

Store in tightly closed original container.

6.5 Nature and composition of immediate packaging


The veterinary product will be supplied in:


250mL and 1L standard high density polyethylene bottles with 28mm polypropylene/high density polyethylene caps.


1L, 2.5L and 5L white flat bottomed heavy duty high density polyethylene back-packs with 38mm white polypropylene easy peel caps.


10L and 20L white high density polyethylene Jerry cans with high density polyethylene caps.


Not all pack sizes may be marketed.


6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products


Extremely dangerous for fish and aquatic life. Do not contaminate ponds, waterways or ditches with the product or used container.

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.


7. MARKETING AUTHORISATION HOLDER

Norbrook Laboratories Limited

Station Works

Newry

Co. Down, BT35 6JP

Northern Ireland


8. MARKETING AUTHORISATION NUMBER


Vm 02000/4358


9. DATE OF FIRST AUTHORISATION


10 December 2013


10. DATE OF REVISION OF THE TEXT


December 2013


Approved: 10/12/2013

Page 7 of 7